Randomised open-label phase II study of induction standard of care fulvestrant and CDK4/ 6 inhibition with addition of ipatasertib in metastatic ER+/HER2-breast cancer patients without circulating tumour (ct) DNA suppression (FAIM)
Okines, A. F. C. Braybrooke, J. MacPherson, I. R. Sutherland, S. Wheatley, D. Waters, S. Roylance, R. Baird, R. D. Oikonomidou, O.
Okines, A. F. C.
Braybrooke, J.
MacPherson, I. R.
Sutherland, S.
Wheatley, D.
Waters, S.
Roylance, R.
Baird, R. D.
Oikonomidou, O.
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2023
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Okines AFC, Braybrooke J, MacPherson IR, Sutherland S, Howell SJ, Wheatley D, et al. Randomised open-label phase II study of induction standard of care fulvestrant and CDK4/ 6 inhibition with addition of ipatasertib in metastatic ER+/HER2-breast cancer patients without circulating tumour (ct) DNA suppression (FAIM). Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772005533.